title: A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
abstract: We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.
authors.affiliation: Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Gray
authors.affiliation: Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT, 06511, USA.
authors.forename: Ran N
authors.initials: RN
authors.lastname: Tao
authors.affiliation: Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: DePorter
authors.affiliation: Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT, 06511, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Spiegel
authors.affiliation: Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA. brian.mcnaughton@colostate.edu.|Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CT, 80523, USA. brian.mcnaughton@colostate.edu.
authors.forename: Brian R
authors.initials: BR
authors.lastname: McNaughton
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D005260:Female; D018734:Genes, erbB-2 / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D015394:Molecular Structure
chemical_list: D000911:Antibodies, Monoclonal
keywords: HER2; activation immunotherapeutic; breast cancer; immunotherapy; nanobody